Emtora Biosciences: Emtora Biosciences Turns Sights on Rare Genetic Disease, New Funding

San Antonio-Emtora Biosciences, a San Antonio biotech startup formerly known as Rapamycin Holdings, is planning to test its drug, eRapa, as a treatment for a rare genetic disease known as Familial Adenomatous Polyposis (FAP). Emtora plans to begin a Phase 2a trial in late 2019 for the condition, which affects 60,000 people in the United [...]